The MEIS2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid cell line, engineered for targeted disruption of the MEIS2 gene. This polyclonal pool provides a heterogeneous loss-of-function model enabling robust assessment of MEIS2-dependent functions without clonal selection artifacts. The knockout strategy employs CRISPR/Cas9-mediated gene disruption to ablate MEIS2 expression, facilitating the study of MEIS2’s roles in transcriptional regulation and hematopoietic malignancies.
The Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt lymphoma-derived B lymphoblastoid model widely used to investigate B-cell lymphoma biology, including proliferation, survival, and drug response mechanisms. Originating from a patient with Burkitt lymphoma, Raji cells maintain key characteristics of aggressive B-cell neoplasms and serve as a relevant platform for functional genomics studies in lymphomagenesis.
MEIS2 encodes a TALE-class homeobox transcription factor that acts as an essential cofactor in HOX/PBX transcriptional complexes. It directly interacts with PBX1, PBX2, and PREP1 to regulate downstream targets such as c-MYC, BCL2, and CDKN1A. MEIS2 activity is modulated by Wnt/??-catenin/TCF, Notch/RBPJ, and TGF-??/SMAD signaling; thus, it integrates signals from ??-catenin, TCF4, SMAD3, and SMAD4 to control proliferation and survival gene programs. Disruption of MEIS2 destabilizes these complexes, impairing transcription of genes that govern cell cycle progression and apoptosis, and altering hematopoietic cellular responses.
In the Raji B-lymphoma background, MEIS2 knockout provides a physiologically relevant model to dissect transcriptional dependencies in aggressive B-cell malignancies. MEIS2 is implicated in regulating c-MYC and BCL2 expression, both central to Burkitt lymphoma pathogenesis; its loss-of-function may therefore attenuate proliferation and enhance apoptotic susceptibility. This model also supports investigation of MEIS2??s role in acute lymphoblastic leukemia and other hematopoietic disorders where its dysregulation is observed. By combining the knockout with pathway modulators, researchers can examine how MEIS2 integrates Wnt, Notch, and TGF-?? inputs to sustain oncogenic transcription and drug resistance.
Applications include ChIP-qPCR and co-immunoprecipitation to assess MEIS2-containing complex formation, RNA-seq and RT-qPCR for transcriptomic profiling, and Western blotting for target validation. Functional analyses such as cell proliferation assays, flow cytometry?Cbased apoptosis and cell cycle readouts, and drug sensitivity screening enable interrogation of MEIS2??s contributions to therapeutic resistance. The polyclonal knockout format permits pooled functional screens and generates data reflective of population-level heterogeneity. For customization or additional details, contact Ascent Research.
